Jefferies upgrades Medpace on biotech funding rebound and limited AI risk - Investing.com
Investing.com -- Jefferies upgraded Medpace to Buy, saying a rebound in biotech funding, a conservative balance sheet and reduced near-term risk ...
Read the original at Investing.com ↗
- Topics
- Markets & Investment
- Tracked via
- “AI Risks”